dsm-firmenich nominates Wanvisa McGinnis as senior account manager for beauty & care in North America

USA –  dsm-firmenich, a global company specializing in nutrition, health, and beauty, has appointed Wanvisa McGinnis as the new senior account manager for Beauty & Care North America.

McGinnis will oversee business development, client engagement, and strategic growth initiatives, strengthening dsm-firmenich’s presence in the region.

McGinnis previously excelled as a sales and business development manager at Cosun Biobased Experts, where she drove market expansion and strategic growth. 

Before that, she was a senior account manager at Lonza, leveraging her expertise in personal care formulations alongside her hands-on experience as a formulation chemist at Physicians Formula and Thibiant International. 

She holds a Bachelor of Science degree from Chulalongkorn University in Bangkok, Thailand.

dsm-firmenich beauty & care segment offers a diverse range of skin care, hair & scalp care, and sun care solutions, integrating synthetic, natural, and biotech ingredients to enhance skin health and protection. 

The company specializes in UV filters, bioactive skin care, peptides, and polymers, delivering scientifically proven formulations tailored to evolving consumer needs.

Q1 FY25 financial highlights

dsm-firmenich has kicked off 2025 with a powerful financial performance, reporting an 8% organic sales growth in the first quarter.

The company’s Q1 trading update, published ahead of its Annual General Meeting on May 6, highlighted broad-based growth across all business units and reaffirmed a bullish outlook for the full year. 

Adjusted EBITDA surged thanks in part to a temporary vitamin price effect, with full-year guidance remaining at a minimum of €2.4 billion(USD 2.58 billion).

“We had a good start to the year, recording 8% organic sales growth in Q1 with positive contributions across all businesses, driving a further improvement in financial performance,” the company stated in its report.

Adjusted EBITDA jumped more than sevenfold to €186 million(USD 200 million), with an improved margin of 21.3%, driven by a 17% increase in pricing and strong underlying performance supported by temporary vitamin price spikes.

“This strong quarter reflects not just favourable market dynamics but the results of our vitamin transformation program,” dsm-firmenich noted.

The company also reported growth across other business segments. 

Perfumery & Beauty experienced strong gains in Perfumery, though performance in Beauty lagged due to weak demand in suncare. 

Looking ahead, dsm-firmenich maintains confidence in its trajectory. 

The FY 2025 guidance includes an expected €150 million(USD 161 million) temporary benefit from vitamin pricing disruptions, €85 million(USD 91 million) of which was realized in Q1, and an anticipated €40 million (USD 43 million)EBITDA impact from the partial deconsolidation following the Feed Enzymes divestment.

Sign up to receive our email newsletters with the latest news updates and insights from Africa and the World HERE.